Haleon (HLN) Income from Non-Controlling Interests (2022 - 2023)

Haleon (HLN) recorded quarterly Income from Non-Controlling Interests of $11.2 million in Q4 2023, down 52.38% on a QoQ basis from $23.5 million in Q4 2022, and down 52.38% year-over-year from $23.5 million in Q4 2022.

Haleon (HLN) Income from Non-Controlling Interests (2022 - 2023) Analysis & Trends

Haleon has disclosed Income from Non-Controlling Interests across 2 years of filings, most recently posting $11.2 million for Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn -
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn -
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn -
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn 22.56 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn -
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn -
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn -
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -
10 Haleon 1.09 Bn -776.09 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 11.17 Mn
Dec 31, 2022 23.46 Mn